Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Arizona for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Arizona only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Arizona (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Sujith Kalmadi (NPI 1508973447)

Field	Value
Entity Type	Individual
Organization	Sujith Kalmadi
Address	695 S Dobson Rd
City	Chandler
State	AZ
ZIP	85224
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	August 24, 2006

Payer Source	Total Paid
Medicare	$2.2M
Medicaid	$0

Key Findings

This provider’s billed Medicare footprint is concentrated and material: Total Medicare revenue is $2.2M while there is no Medicaid billing on file (none below), making the practice effectively single‑payer (Medicare) in scale for public programs. The NPI was enumerated on 2006-08-24 (~20 years ago), indicating a long-tenured operation that is still primarily Medicare-facing.

Revenue is highly concentrated in anti‑cancer biologics: the precomputed top‑3 Medicare codes (J9299, J9271, Q5118) account for 73.4% of this provider’s Medicare revenue. Those three entries are J9299 $813.6K (36.9%), J9271 $683.7K (31.0%), and Q5118 $118.9K (5.4%), which together drive the majority of the $2.2M lifetime Medicare receipts and imply sensitivity to reimbursement or utilization changes for these agents.

The code mix indicates a specialty oncology infusion model dominated by checkpoint inhibitors and biosimilars: high revenues for J9299 (nivolumab) and J9271 (pembrolizumab) plus Q5118 (bevacizumab‑bvzr biosimilar) point to routine, high-volume administration of systemic immunotherapies and targeted agents. Supportive chemotherapy administration and infusion add‑on codes (96413, 96417, 96415, 96367, G0498) and procedural drug codes (J0897, J9217, J1439, J0640) further characterize this as an infusion‑centric hematology/oncology practice rather than a predominantly inpatient or surgical practice.

Competitive standing for the top drug codes is mixed: J9299 ranks #56 of 505 providers nationally (89th percentile; typical, unremarkable volume), J9271 ranks #625 of 1841 (66th percentile; typical, unremarkable volume), and Q5118 ranks #19 of 161 (89th percentile; typical, unremarkable volume). In plain terms, the provider is a solid participant in national immunotherapy billing for these agents—not the very top national outlier but above median for comparable oncology practices, particularly for the biosimilar where the provider is among the higher users in a smaller cohort.

Several service lines show statistically elevated utilization compared with national peers: the office E/M code 99213 has 1.4K claims and $89.8K revenue and ranks #2645 of 457151 providers nationally (99th percentile; extreme outlier), and the tele/remote code 99442 (288 claims, $18.1K) ranks #413 of 21242 providers (98th percentile; notably above typical national volume). These extremes suggest unusually high outpatient visit and remote‑contact volumes relative to national norms for providers overall, which may reflect practice throughput or care‑coordination patterns in this oncology setting.

Chemotherapy administration metrics reinforce an active infusion service line: 96413 (582 claims, $57K) ranks #446 of 7514 (94th percentile; notably above typical national volume) and 96417 (219 claims, $10.7K) ranks #175 of 3014 (94th percentile; notably above typical national volume). At the same time, other infusion/add‑on codes such as 96415 (228 claims, $4.8K) rank #464 of 4959 (91th percentile; typical, unremarkable volume), indicating consistently above‑typical chemotherapy administration intensity without being uniformly extreme across every administration code.

Imaging and diagnostic support is present but not outsized: PET/CT related codes 78815 ($118.4K), 78816 ($32.8K) and diagnostic radiotracer A9552 ($37.9K) together represent visible imaging revenue lines (each reported at typical national percentiles: 78815 70th, 78816 57th, A9552 79th). Additional CT codes (74177, 71260) appear in the top 25 at typical percentiles, suggesting the practice either refers for or directly manages a regular complement of oncology imaging alongside systemic therapy rather than relying on imaging as its primary revenue driver.

Taken together, the long tenure (NPI enumerated 2006-08-24 (~20 years ago)), concentrated revenue in a small set of high-cost oncology drugs, and pockets of extreme outpatient visit/telehealth volume paint a picture of a mature, infusion‑oriented hematology/oncology practice that is heavily Medicare‑dependent and operationally centered on immunotherapy/chemotherapy administration with integrated imaging and follow‑up care.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

49 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9299	Injection, nivolumab, 1 mg	33,900	$20	$813.6K
J9271	Injection, pembrolizumab, 1 mg	15,900	$40	$683.7K
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	5,170	$20	$118.9K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	110	$1,120	$118.4K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	1,400	$60	$89.8K
J0897	Injection, denosumab, 1 mg	3,300	$20	$62.7K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	580	$100	$57K
A9552	Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries	140	$280	$37.9K
78816	The patient is injected with a radiopharmaceutical tracer called FDG (fluoro–deoxyglucose, a radioactive substance containing glucose) about one hour before the imaging is scheduled to begin. The…	30	$1,090	$32.8K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	240	$140	$32.5K

Showing 1–10 of 49

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 49 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Arizona Distribution

Sujith Kalmadi — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Arizona

Full comparison — all codes billed, vs. state median

49 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	14	80	10,000	$40	$487.4K
J9299	3	30	7,480	$20	$290K
J0897	118	260	2,940	$20	$115.6K
78815	37	160	60	$710	$75.8K
Q5118	2	20	1,290	$20	$44.4K
J1439	32	50	30,380	$1	$30K
96413	22	230	190	$100	$24.8K
A9552	19	120	50	$260	$20.8K
99214	6,231	10,410	120	$80	$20.6K
J9217	23	140	120	$130	$19.7K

Showing 1–10 of 49

Related Providers

Other providers that share a Tax Identification Number (TIN) with Sujith Kalmadi, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Ironwood Physicians, PC	AZ	Hematology & Oncology Physician	$0	$7.3M
Rakesh Bagai	AZ	Hematology & Oncology Physician	$4.6M	$0
Alice Tsai	AZ	Radiation Oncology Physician	$1.7M	$0
Charles Woo	AZ	Radiation Oncology Physician	$1.5M	$0
Ronik Bhangoo	AZ	Radiation Oncology Physician	$1.5M	$0
Pranshu Bansal	AZ	Hematology & Oncology Physician	$1.4M	$0
Murali Murty	AZ	Radiation Oncology Physician	$1.3M	$0
Luke Halbur	AZ	Hematology & Oncology Physician	$1.3M	$0
Rajesh Kukunoor	AZ	Hematology & Oncology Physician	$1.2M	$0
Robert Yoo	AZ	Hematology & Oncology Physician	$1.1M	$0

Nearby Providers

Other providers in the same ZIP code as Sujith Kalmadi, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Arion Care Solutions, LLC	AZ	In Home Supportive Care Agency	$0	$608.8M
Dignity Community Care	AZ	General Acute Care Hospital	$0	$71M
Momdoc, LLC	AZ	Obstetrics & Gynecology Physician	$0	$63.3M
Valley Perinatal Services, LLC	AZ	Maternal & Fetal Medicine Physician	$0	$23.6M
Amy Grulke, PLLC	AZ	Speech-Language Pathologist	$0	$21M
Phoenix Neurological Institute, Inc	AZ	Neurology Physician	$0	$18M
360 Physical Therapy LLC	AZ	Multi-Specialty Clinic/Center	$0	$16.8M
Phoenician Medical Center, Inc	AZ	Family Medicine Physician	$0	$15.7M
Twelfth One, LLC	AZ	Home Infusion Therapy Pharmacy	$0	$14.3M
Chandler Emergency Medical Group, LLC	AZ	Emergency Medicine Physician	$0	$14.3M

Sujith Kalmadi — Billing Profile & Reimbursement Data

Sign up for Sujith Kalmadi — Billing Profile & Reimbursement Data policy alerts

Sujith Kalmadi — Billing Profile & Reimbursement Data

Sign up for Sujith Kalmadi — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References